Skip to main content
Clinical Trials/NCT04293354
NCT04293354CompletedNot Applicable

Analgesic Efficacy of Serratus Anterior Plane Block in The Rib Fractures Pain

Kahramanmaras Sutcu Imam University2 sites in 2 countries60 target enrollmentStarted: August 1, 2017Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
60
Locations
2
Primary Endpoint
Analgesic consumption

Study Overview

Brief Summary

Serratus Anterior Plane Block (SAPB) is a facial plane block that was first described by Blanco in 2013 and that blocks the lateral cutaneous branches of the T2-T9 intercostal nerves, the intercostobrachial nerve, n. thoracic longus, n. thoracodorsalis nerves. Case and case series have been reported in the literature on the use of SAPB in rib fractures, and it has been reported as an effective analgesia method. We apply SAPB to patients with rib fractures with pain in our clinic.

Our aim is to evaluate SAPB for patients with rib fractures pain and to compare them with the control group in terms of total analgesic consumption and pain scores.

Detailed Description

After Ethics Committee approval patients with rib fracture pain and have a Numerical Rating Scale (NRS) score of ≥ 4, included the study. The patients were randomized by the closed envelope method. The patients were divided into two groups as the SAPB-performed group (Group S) and the Control group (Group K). Intravenous patient-controlled analgesia (PCA) device prepared with tramadol was applied to all patients.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
Double (Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 90 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Rib fracture pain and had a Numerical Rating Scale (NRS) score of ≥ 4 ASA I-II-III

Exclusion Criteria

  • Patients with infection at the injection site Coagulopathy Allergy to amide-type local anesthetics History of peripheral neuropathy Hepatic and/or renal failure Refusing the procedure

Outcomes

Primary Outcomes

Analgesic consumption

Time Frame: up to 24 hour

Tramadol

Secondary Outcomes

  • Numerical Rating Scale (NRS)(at 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours)

Investigators

Sponsor
Kahramanmaras Sutcu Imam University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Gözen Öksüz

associate professor

Kahramanmaras Sutcu Imam University

Study Sites (2)

Loading locations...

Similar Trials